Type 1 vs Type 2 Diabetes Blood Tests: What’s Different and What to Expect
Type 1 vs Type 2 diabetes blood tests are best understood as answering two separate questions. First: does laboratory testing show hyperglycaemia at a level consistent with diabetes? Second: if diabetes is present, what evidence supports classification as type 1 or type 2? The first question can involve overlapping glucose-based tests, while the second may require clinical assessment, diabetes-specific autoantibodies and, in selected uncertain cases, C-peptide. HbA1c of 48 mmol/mol (6.5%) or above is an accepted diagnostic threshold in suitable circumstances, but HbA1c should not be used to diagnose suspected type 1 diabetes.[1][2]
| Feature | Type 1 diabetes | Type 2 diabetes |
|---|---|---|
| Confirming hyperglycaemia | Blood glucose-based assessment; HbA1c is not appropriate for diagnosing suspected type 1 diabetes | HbA1c and/or glucose-based criteria may be used when appropriate |
| Classification | Clinical assessment plus diabetes-specific autoantibodies | Usually classified from clinical context after diabetes is confirmed; additional tests may be used if the type is uncertain |
| Autoantibodies | Recommended by NICE when type 1 diabetes is initially considered; two different autoantibodies reduce false negatives | Not routine for typical type 2 diabetes, but may be relevant when classification is uncertain |
| C-peptide | Not routinely recommended simply to confirm type 1; considered when autoantibodies are negative and classification remains uncertain | Can help assess endogenous insulin production in selected classification questions |
| Ongoing HbA1c monitoring | Every 3–6 months in adults, according to NICE | Individualised targets; typically every 3–6 months until stable and every 6 months once stable |
Step 1 — Confirming Diabetes Is Present (Tests Used for Both Types)
The first laboratory question is whether blood glucose is raised to a level that meets accepted diagnostic criteria. This is separate from deciding which type of diabetes is most likely. Glucose-based testing may involve fasting plasma glucose, random plasma glucose in the appropriate clinical setting or an oral glucose tolerance test. HbA1c is also widely used for diagnosis when the circumstances are suitable.
Diabetes UK states that an HbA1c of 48 mmol/mol (6.5%) or above is an accepted diagnostic cut-off in appropriate circumstances.[2] However, HbA1c is not suitable for every diagnostic situation. One of the most important exceptions is suspected type 1 diabetes, where waiting for HbA1c-based confirmation may be inappropriate.
That distinction matters because type 1 diabetes can develop rapidly. NICE guidance for adults advises that type 1 diabetes is initially diagnosed on clinical grounds in a person with hyperglycaemia, rather than by relying on HbA1c to settle the diagnosis.[1]
In other words, the laboratory confirmation of hyperglycaemia and the classification of diabetes type are related but not identical steps.
Step 2 — Classifying the Type (Where T1 and T2 Diverge)
Once diabetes-level hyperglycaemia is established, clinicians consider whether the pattern is more consistent with type 1, type 2 or another form of diabetes. Clinical features such as the speed of symptom development, body weight, age, ketosis, personal and family history, treatment response and associated autoimmune disease can all contribute to classification.
NICE specifically warns against relying on age or body mass index alone. Adults can develop type 1 diabetes at many ages, and people with type 1 diabetes can be overweight. Conversely, younger adults can develop type 2 diabetes. Laboratory evidence therefore becomes especially useful when the clinical picture is not straightforward.
For adults initially considered to have type 1 diabetes, NICE recommends measuring diabetes-specific autoantibodies. These tests look for evidence of autoimmune activity directed against pancreatic beta-cell antigens. Measuring two different autoantibodies helps reduce the chance of a false-negative result.[1]
HbA1c — Used in Both, But With Important Limits for Type 1
HbA1c reflects average glycaemic exposure over roughly the previous two to three months because glucose attaches to haemoglobin within circulating red blood cells. It is extremely useful for long-term monitoring in both type 1 and type 2 diabetes.
For diagnosis, however, the context matters. Diabetes UK identifies suspected type 1 diabetes as a situation in which HbA1c is not appropriate for diagnosis.[2] A person can have clinically important recent hyperglycaemia even though the HbA1c has not yet risen enough to reflect the rapid change.
HbA1c can also be misleading when red-cell lifespan or haemoglobin biology is altered. That is why clinicians may use plasma glucose criteria instead when HbA1c is unsuitable.
For ongoing management, HbA1c remains central. NICE recommends measuring HbA1c every 3–6 months in adults with type 1 diabetes.[1] In type 2 diabetes, the HbA1c target should be individualised rather than treated as one universal goal.[3]
Autoantibody Tests (GAD, IA-2, ZnT8) — Type 1 Specific
Type 1 diabetes is usually an autoimmune disease in which immune activity contributes to destruction of insulin-producing pancreatic beta cells. Laboratory autoantibody testing can provide evidence that supports this classification.
Common diabetes-specific autoantibodies include antibodies against glutamic acid decarboxylase (GAD), islet antigen-2 (IA-2) and zinc transporter 8 (ZnT8). The exact panel offered varies by laboratory.
NICE recommends measuring diabetes-specific autoantibodies in adults initially considered to have type 1 diabetes and notes that the false-negative rate is reduced by measuring two different diabetes-specific autoantibodies.[1]
A positive autoantibody result can support autoimmune type 1 classification, but a negative result does not automatically prove type 2 diabetes. Autoantibody positivity can change with time, not every person with type 1 diabetes has detectable antibodies on every panel, and other types of diabetes also exist. This is where C-peptide may become useful in selected uncertain cases.
C-Peptide Test — When and Why It Is Used
C-peptide is released when the pancreas produces endogenous insulin. Measuring it can therefore give information about how much insulin the person’s own beta cells are still making. This makes C-peptide potentially useful when the clinical question is whether endogenous insulin production is preserved.
However, NICE does not recommend routine C-peptide testing simply to confirm type 1 diabetes in adults.[1] Instead, C-peptide is considered when diabetes-specific autoantibodies are negative and the classification remains uncertain.
NICE recommends a non-fasting C-peptide measurement with a paired blood glucose result in this selected situation. The paired glucose matters because C-peptide should be interpreted in relation to the glucose level at the time of sampling.
An important nuance is timing. The ability of C-peptide to distinguish type 1 from type 2 diabetes generally improves with time after initial diagnosis because endogenous insulin production tends to decline in type 1 diabetes while it is more often retained, at least initially, in type 2 diabetes.[1]
Ongoing Monitoring Tests for Both Types
After diagnosis and classification, laboratory testing shifts from “what type is this?” towards monitoring glycaemic control and screening for complications.
For adults with type 1 diabetes, NICE recommends measuring HbA1c every 3–6 months.[1] Day-to-day glucose management may also use continuous glucose monitoring or capillary blood glucose testing, depending on the individual care plan.
For type 2 diabetes, NICE recommends measuring HbA1c every 3–6 months until HbA1c and glucose-lowering therapy are stable, and every 6 months once they are stable.[3] HbA1c targets are individualised, taking account of treatment, comorbidities, hypoglycaemia risk and personal circumstances.
Both types also require broader health monitoring. Depending on the person’s care plan, this may include renal function, urinary albumin measurements, lipid testing and other assessments used to reduce long-term cardiovascular, kidney and microvascular risk.
What Your Results Mean
A useful way to interpret diabetes laboratory results is to keep the two questions separate:
- Does the result support diabetes-level hyperglycaemia? This may be assessed with plasma glucose tests or HbA1c when HbA1c is appropriate.
- What supports the classification? Clinical features, diabetes-specific autoantibodies and selected use of C-peptide can help distinguish type 1 from type 2 when the picture is uncertain.
An HbA1c at or above 48 mmol/mol can support a diabetes diagnosis in appropriate circumstances, but it should not be used as the diagnostic method for suspected type 1 diabetes.[2]
A positive diabetes-specific autoantibody can support autoimmune classification. A negative result does not by itself prove type 2 diabetes, which is why NICE recommends using clinical judgement and considering C-peptide when uncertainty remains.[1]
C-peptide is therefore not a routine “type 1 confirmation test”. Its role is more targeted: helping resolve difficult classification questions, particularly after time has passed and the distinction in endogenous insulin secretion may be clearer.
Frequently Asked Questions
Is HbA1c used to diagnose both type 1 and type 2 diabetes?
HbA1c can be used to diagnose diabetes in appropriate circumstances, with 48 mmol/mol (6.5%) or above being an accepted cut-off. However, HbA1c is not appropriate for diagnosing suspected type 1 diabetes because type 1 may develop too rapidly for HbA1c to reflect the acute change.[2]
Which blood test tells the difference between type 1 and type 2 diabetes?
There is no single universal test that classifies every case. NICE recommends combining clinical assessment with diabetes-specific autoantibodies for adults initially considered to have type 1 diabetes. C-peptide can be considered when antibodies are negative and uncertainty remains.[1]
Which autoantibodies are tested for type 1 diabetes?
Panels may include GAD, IA-2 and ZnT8 antibodies, depending on the laboratory. NICE recommends measuring diabetes-specific autoantibodies and notes that using two different autoantibodies reduces false negatives.[1]
Is C-peptide routinely required to confirm type 1 diabetes?
No. NICE advises against routine C-peptide testing simply to confirm type 1 diabetes. It is considered when autoantibodies are negative and classification remains uncertain, with a non-fasting C-peptide interpreted alongside a paired blood glucose.[1]
How often is HbA1c checked in type 1 diabetes?
NICE recommends HbA1c measurement every 3–6 months in adults with type 1 diabetes.[1]
How often is HbA1c checked in type 2 diabetes?
NICE recommends measurement every 3–6 months until HbA1c and glucose-lowering treatment are stable, then every 6 months once stable. Targets are individualised.[3]
References
- National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management — Recommendations. NICE guideline NG17. Reviewed 30 January 2026. https://www.nice.org.uk/guidance/ng17/chapter/Recommendations
- Diabetes UK. Diagnostic criteria for diabetes. https://www.diabetes.org.uk/for-professionals/improving-care/clinical-recommendations-for-professionals/diagnosis-ongoing-management-monitoring/new_diagnostic_criteria_for_diabetes
- National Institute for Health and Care Excellence. Type 2 diabetes in adults: management — Blood glucose management. NICE guideline NG28. Updated 18 February 2026. https://www.nice.org.uk/guidance/ng28/chapter/Blood-glucose-management
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional about your results.